347 related articles for article (PubMed ID: 28315733)
1. WT1 ameliorates podocyte injury via repression of EZH2/β-catenin pathway in diabetic nephropathy.
Wan J; Hou X; Zhou Z; Geng J; Tian J; Bai X; Nie J
Free Radic Biol Med; 2017 Jul; 108():280-299. PubMed ID: 28315733
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-27a promotes podocyte injury via PPARγ-mediated β-catenin activation in diabetic nephropathy.
Zhou Z; Wan J; Hou X; Geng J; Li X; Bai X
Cell Death Dis; 2017 Mar; 8(3):e2658. PubMed ID: 28277542
[TBL] [Abstract][Full Text] [Related]
3. The Histone Methyltransferase Enzyme Enhancer of Zeste Homolog 2 Protects against Podocyte Oxidative Stress and Renal Injury in Diabetes.
Siddiqi FS; Majumder S; Thai K; Abdalla M; Hu P; Advani SL; White KE; Bowskill BB; Guarna G; Dos Santos CC; Connelly KA; Advani A
J Am Soc Nephrol; 2016 Jul; 27(7):2021-34. PubMed ID: 26534922
[TBL] [Abstract][Full Text] [Related]
4. Celastrol attenuates diabetic nephropathy by upregulating SIRT1-mediated inhibition of EZH2related wnt/β-catenin signaling.
Tang Y; Wan F; Tang X; Lin Y; Zhang H; Cao J; Yang R
Int Immunopharmacol; 2023 Sep; 122():110584. PubMed ID: 37454630
[TBL] [Abstract][Full Text] [Related]
5. Lysophosphatidic Acid Induces Podocyte Pyroptosis in Diabetic Nephropathy by an Increase of Egr1 Expression via Downregulation of EzH2.
Kim D; Ban KY; Lee GH; Jun HS
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373116
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-466o-3p mediates β-catenin-induced podocyte injury by targeting Wilms tumor 1.
Chen Q; Chen J; Wang C; Chen X; Liu J; Zhou L; Liu Y
FASEB J; 2020 Nov; 34(11):14424-14439. PubMed ID: 32888352
[TBL] [Abstract][Full Text] [Related]
7. Mutual antagonism of Wilms' tumor 1 and β-catenin dictates podocyte health and disease.
Zhou L; Li Y; He W; Zhou D; Tan RJ; Nie J; Hou FF; Liu Y
J Am Soc Nephrol; 2015 Mar; 26(3):677-91. PubMed ID: 25071087
[TBL] [Abstract][Full Text] [Related]
8. AGE-Induced Suppression of EZH2 Mediates Injury of Podocytes by Reducing H3K27me3.
Liebisch M; Wolf G
Am J Nephrol; 2020; 51(9):676-692. PubMed ID: 32854097
[TBL] [Abstract][Full Text] [Related]
9. Protection of CTGF Antibody Against Diabetic Nephropathy in Mice Via Reducing Glomerular β-Catenin Expression and Podocyte Epithelial-Mesenchymal Transition.
Dai HY; Ma LN; Cao Y; Chen XL; Shi H; Fan YP; Yang B
J Cell Biochem; 2017 Nov; 118(11):3706-3712. PubMed ID: 28370212
[TBL] [Abstract][Full Text] [Related]
10. LncRNA MALAT1 is dysregulated in diabetic nephropathy and involved in high glucose-induced podocyte injury via its interplay with β-catenin.
Hu M; Wang R; Li X; Fan M; Lin J; Zhen J; Chen L; Lv Z
J Cell Mol Med; 2017 Nov; 21(11):2732-2747. PubMed ID: 28444861
[TBL] [Abstract][Full Text] [Related]
11. Silencing of long noncoding RNA PVT1 inhibits podocyte damage and apoptosis in diabetic nephropathy by upregulating FOXA1.
Liu DW; Zhang JH; Liu FX; Wang XT; Pan SK; Jiang DK; Zhao ZH; Liu ZS
Exp Mol Med; 2019 Aug; 51(8):1-15. PubMed ID: 31371698
[TBL] [Abstract][Full Text] [Related]
12. Effect of Tang-Shen-Ning decoction on podocyte epithelial-esenchymal transformation via inhibiting Wnt/β-catenin pathway in diabetic mice.
Cui FQ; Gao YB; Wang YF; Meng Y; Cai Z; Shen C; Jiang XC; Zhao WJ
Ann Palliat Med; 2021 Dec; 10(12):12921-12936. PubMed ID: 32921066
[TBL] [Abstract][Full Text] [Related]
13. Semaphorin3a promotes advanced diabetic nephropathy.
Aggarwal PK; Veron D; Thomas DB; Siegel D; Moeckel G; Kashgarian M; Tufro A
Diabetes; 2015 May; 64(5):1743-59. PubMed ID: 25475434
[TBL] [Abstract][Full Text] [Related]
14. Wilms tumor suppressor, WT1, suppresses epigenetic silencing of the β-catenin gene.
Akpa MM; Iglesias DM; Chu LL; Cybulsky M; Bravi C; Goodyer PR
J Biol Chem; 2015 Jan; 290(4):2279-88. PubMed ID: 25331950
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms' tumor-1 protein used as a podocyte marker.
Su J; Li SJ; Chen ZH; Zeng CH; Zhou H; Li LS; Liu ZH
Diabetes Res Clin Pract; 2010 Feb; 87(2):167-75. PubMed ID: 19969384
[TBL] [Abstract][Full Text] [Related]
16. Shifts in podocyte histone H3K27me3 regulate mouse and human glomerular disease.
Majumder S; Thieme K; Batchu SN; Alghamdi TA; Bowskill BB; Kabir MG; Liu Y; Advani SL; White KE; Geldenhuys L; Tennankore KK; Poyah P; Siddiqi FS; Advani A
J Clin Invest; 2018 Jan; 128(1):483-499. PubMed ID: 29227285
[TBL] [Abstract][Full Text] [Related]
17. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
Chen Q; Zheng PS; Yang WT
Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
[TBL] [Abstract][Full Text] [Related]
18. Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats.
Chen J; Chen Y; Luo Y; Gui D; Huang J; He D
Eur J Pharmacol; 2014 Aug; 736():86-94. PubMed ID: 24809932
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of transcriptional coactivator YAP Impairs the expression and function of transcription factor WT1 in diabetic podocyte injury.
Chen J; Wang X; He Q; Yang HC; Fogo AB; Harris RC
Kidney Int; 2024 Jun; 105(6):1200-1211. PubMed ID: 38423183
[TBL] [Abstract][Full Text] [Related]
20. Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling.
Liu M; Liang K; Zhen J; Zhou M; Wang X; Wang Z; Wei X; Zhang Y; Sun Y; Zhou Z; Su H; Zhang C; Li N; Gao C; Peng J; Yi F
Nat Commun; 2017 Sep; 8(1):413. PubMed ID: 28871079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
